Progress Report on Studies of FAM-CF for Gastric Cancer and Intraperitoneal Administration of FUra-CF Followed by Cisplatin (DDP)

  • S. G. Arbuck
  • H. O. DouglassJr.
  • H. R. Nava
  • Y. N. Silk
  • M. Baroni
  • Y. M. Rustum
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)


Randomized controlled trials have demonstrated that the response rate to 5-fluorouracil (FUra) in combination with leucovorin (CF) is approximately two-fold higher than the response rate to single agent FUra in patients with colorectal carcinoma (1–5). Since FUra alone has activity in other gastrointestinal cancers, our work has been directed toward evaluating the role of this combination for the treatment of other gastrointestinal cancers, using both the intravenous (IV) and intraperitoneal (IP) routes.


Gastric Cancer Folinic Acid Intraperitoneal Chemotherapy Measurable Disease Malignant Ascites 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Doroshow JH, Bertrand M, Multhauf P, et al: Prospective Randomized Trial of 5-FU versus 5-FU and High-Dose Folinic Acid (HDFA) for Treatment of Advanced Colorectal Cancer. Proc Am Soc Clin Oncol 6: 96, 1987Google Scholar
  2. 2.
    Petrelli N, Herrera L, Rustum YM, et al: A Prospective Randomized Trial of 5-Fluorouracil versus 5-Fluorouracil and High-Dose Leucovorin versus 5-Fluorouracil and Methotrexate in Previously Untreated Patients with Advanced Colorectal Carcinoma. J Clin Oncol 5: 1559–1565, 1987PubMedGoogle Scholar
  3. 3.
    Erlichman C, Fine S, Wong A, et al: A Randomized Trial of Fluorouracil and Folinic Acid in Patients with Metastatic Colorectal Cancer. J Clin Oncol 6: 469–475, 1988PubMedGoogle Scholar
  4. 4.
    Petrelli N, Stablein D, Bruckner H, et al: Phase III Evaluation of 5-Fluorouracil (5-FU) vs 5-FU and High-Dose Leucovorin (HDCF) vs 5-FU and Low-Dose Leucovorin (LDCF) in Patients with Metastatic Colorectal Adenocarcinoma. A Report of the Gastrointestinal Tumor Study Group. Proc Am Soc Clin Oncol, In Press, 1988Google Scholar
  5. 5.
    O’Connell MJ and Wieand HS: A Controlled Clinical Trial Including Folinic Acid at Two Distinct Dose Levels in Combination with 5-Fluorouracil (5FU) for the Treatment of Advanced Colorectal Cancer: Experience of the Mayo Clinic and North Central Cancer Treatment Group, Proceedings of the International Symposium on “The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy”. Buffalo, NY, April 1988Google Scholar
  6. 6.
    Arbuck SG, Douglass HO Jr, Trave F, et al: A Phase II Trial of 5-Fluorouracil and High-Dose Intravenous Leucovorin in Gastric Carcinoma. J Clin Oncol 5: 1150–1156, 1987PubMedGoogle Scholar
  7. 7.
    Machover D, Goldschmidt E, Chollet P, et al: Treatment of Advanced Colorectal and Gastric Adenocarcinomas with 5-Fluorouracil and High Dose Folinic Acid. J Clin Oncol 4: 685–696, 1986PubMedGoogle Scholar
  8. MacDonald JS, Schein PS, Wooley PV: 5-Fluorouracil, Doxorubicin and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer. Ann Intern Med 93: 533–536, 1980Google Scholar
  9. 9.
    Speyer, JL, Collins JM, Dedrick, R L, et al: Phase I and Pharmacological Studies of 5-Fluorouracil Administered Intraperitoneally. Cancer Res 40: 567–572, 1980PubMedGoogle Scholar
  10. 10.
    Arbuck SG, Trave F, Douglass HO, Jr, et al: Phase I and Pharmacologic Studies of Intraperitoneal Leucovorin and 5-Fluorouracil in Patients with Advanced Cancer. J Clin Oncol 4: 1510–1517, 1986PubMedGoogle Scholar
  11. 11.
    Speyer, JL, Sugarbaker PH, Collins, JM, et al: Portal Levels and Hepatic Clearance of 5-Fluorouracil After Intraperitoneal Administration in Humans. Cancer Res 41: 1916–1922, 1981PubMedGoogle Scholar
  12. 12.
    Taylor I, Machin D, Mullee M: A Randomized Controlled Trial of Adjuvant Portal Vein Cytotoxic Perfusion in Colorectal Cancer. Br J Surg 72: 359–363, 1985PubMedCrossRefGoogle Scholar
  13. 13.
    Trave F, Rustum YM, Goranson J: Synergistic Antitumor Activity of Cisplatin (DDP) and 5-Fluorouracil in Mice Bearing Leukemia L1210 Cells. Proc Am Assoc Cancer Res 26: 322, 1985Google Scholar
  14. 14.
    Rustum YM, Trave F: Personal CommunicationGoogle Scholar
  15. 15.
    Dunnick, NR, Jones RB, Doppman JL, et al: Intraperitoneal Contrast Infusion for Assessment of Intraperitoneal Fluid Dynamics. Am J Rad 133: 221–223, 1979Google Scholar
  16. 16.
    Douglass, HO Jr, Lavin PT, Goudsmit A, et al: An Eastern Cooperative Oncology Group Evaluation of Combinations of Methyl-CCNU, Mitomycin C, Adriamycin, and 5-Fluorouracil in Advanced Measurable Gastric Cancer (EST 2277). J Clin Onc 2: 1372–1381, 1984Google Scholar
  17. 17.
    Ozols RF, Locker GY, Doroshow JH, et al: Pharmacokinetics of Adriamycin and Tissue Penetration in Murine Ovarian Cancer. Cancer Res 39: 3209–3214, 1979PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • S. G. Arbuck
    • 1
  • H. O. DouglassJr.
    • 1
  • H. R. Nava
    • 1
  • Y. N. Silk
    • 1
  • M. Baroni
    • 1
  • Y. M. Rustum
    • 1
  1. 1.Roswell Park Memorial InstituteBuffaloUSA

Personalised recommendations